Equillium, Inc.
EQ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001746466
No open-market purchases or sales by Equillium, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $133.0M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Equillium, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 28 | 27 | −1 |
| Shares | 10.8M | 9.92M | −847.6K (−7.9%) |
| Value | $7.86M | $7.44M | −$422.3K (−5.4%) |
New holders (4)
Institutions that held Equillium, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Prudential Financial Inc | 57,800 | $43.4K | 0.00% |
| Simplex Trading, LLC | 2,070 | $1.00K | 0.00% |
| FMR LLC | 25 | $19 | 0.00% |
| Royal Bank of Canada | 467 | $0 | 0.00% |
Sold out (5)
Institutions that held Equillium, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Samsara BioCapital, LLC | 615,541 | $449.3K |
| Victory Capital Management Inc | 345,861 | $252.5K |
| Virtu Financial LLC | 18,724 | $14.0K |
| Susquehanna International Group, LLP | 14,814 | $10.8K |
| UBS Group AG | 6,043 | $4.41K |